BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-09 |
2024-06 |
-0.56 |
N/A |
N/A |
N/A |
2024-03-29 |
2023-12 |
-0.65 |
-0.57 |
0.08 |
12.31% |
2023-11-13 |
2023-09 |
-0.68 |
-0.64 |
0.04 |
5.88% |
2023-08-11 |
2023-06 |
-1.56 |
-0.77 |
0.79 |
50.64% |
2023-03-24 |
2022-12 |
0 |
N/A |
N/A |
N/A |
2022-11-14 |
2022-09 |
-0.49 |
-1.28 |
-0.79 |
-161.22% |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
Roth MKM |
Upgrade |
Buy |
Buy |
2022-12-06 |
Roth Capital |
Upgrade |
|
Buy |
2022-09-27 |
Maxim Group |
Upgrade |
|
Buy |
2021-11-30 |
Roth Capital |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-09-14 |
ALSTODT LANCE |
Chief Executive Officer |
189.51K |
Purchase |
2024-02-08 |
BROADRICK DALE |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2018-05-08 |
CATELL ROBERT B |
Director |
80.87K |
Purchase |
2017-02-28 |
DESMARAIS JOHN M |
Director and Beneficial Owner of more than 10% of a Class of Security |
493.40K |
Stock Award(Grant) |
2022-06-14 |
KRISTAL ROBERT EUGENE |
Chief Financial Officer |
7.99K |
Purchase |
2019-08-27 |
RADOV A JEFFREY |
Director |
24.50K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
126.96K |
559.88K |
14.56% |
2023-06-29 |
Wealth Alliance |
44.32K |
195.43K |
5.08% |
2023-06-29 |
Geode Capital Management, LLC |
43.78K |
193.05K |
5.02% |
2023-06-29 |
Mariner, LLC |
26.67K |
117.61K |
3.06% |
2023-06-29 |
Two Sigma Advisers, LP |
26.30K |
115.98K |
3.02% |
2023-06-29 |
State Street Corporation |
20.46K |
90.22K |
2.35% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
121.05K |
533.81K |
13.88% |
2023-05-30 |
Fidelity Extended Market Index Fund |
6.91K |
35.93K |
0.79% |
2023-06-29 |
Vanguard Extended Market Index Fund |
5.91K |
26.06K |
0.68% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
3.86K |
20.08K |
0.44% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
1.39K |
7.20K |
0.16% |
2023-06-29 |
Blackstone Alternative Multi-Strategy Fund |
400.00 |
1.76K |
0.05% |
Split |
Date |
1 : 4000 |
2021-10-27 |
1 : 20 |
2015-07-07 |
0.02 : 1 |
2013-04-15 |